Condition: Metastatic Pancreatic Ductal Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Sponsor: University of Miami
The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions faster than the current standard approach, which is to wait 8 weeks after starting chemotherapy to obtain participant first imaging scans since starting chemotherapy.
This description comes directly from the study's public registry record.
Siudy Vasquez · (305) 243-2647 · sxv507@med.miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096362